Extracellular vesicles in DLBCL provide abundant clues to aberrant transcriptional programming and genomic alterations.
Document Type
Article
Publication Date
8-16-2018
JAX Source
Blood 2018 Aug 16; 132(7):e13-e23
Volume
132
Issue
7
First Page
13
Last Page
13
ISSN
1528-0020
PMID
29967128
DOI
https://doi.org/10.1182/blood-2017-12-821843
Abstract
The biological role of extracellular vesicles (EVs) in diffuse large B-cell lymphoma (DLBCL) initiation and progression remains largely unknown. We characterized EVs secreted by 5 DLBCL cell lines, a primary DLBCL tumor, and a normal control B-cell sample, optimized their purification, and analyzed their content. We found that DLBCLs secreted large quantities of CD63, Alix, TSG101, and CD81 EVs, which can be extracted using an ultracentrifugation-based method and traced by their cell of origin surface markers. We also showed that tumor-derived EVs can be exchanged between lymphoma cells, normal tonsillar cells, and HK stromal cells. We then examined the content of EVs, focusing on isolation of high-quality total RNA. We sequenced the total RNA and analyzed the nature of RNA species, including coding and noncoding RNAs. We compared whole-cell and EV-derived RNA composition in benign and malignant B cells and discovered that transcripts from EVs were involved in many critical cellular functions. Finally, we performed mutational analysis and found that mutations detected in EVs exquisitely represented mutations in the cell of origin. These results enhance our understanding and enable future studies of the role that EVs may play in the pathogenesis of DLBCL, particularly with regards to the exchange of genomic information. Current findings open a new strategy for liquid biopsy approaches in disease monitoring.
Recommended Citation
Rutherford S,
Fachel A,
Li S,
Sawh S,
Muley A,
Ishii J,
Saxena A,
Dominguez P,
Caldas Lopes E,
Agirre X,
Chambwe N,
Correa F,
Jiang Y,
Richards K,
Betel D,
Shaknovich R.
Extracellular vesicles in DLBCL provide abundant clues to aberrant transcriptional programming and genomic alterations. Blood 2018 Aug 16; 132(7):e13-e23